Article thumbnail

Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

By Christopher J. A. Duncan, Susanne H. Sheehy, Katie J. Ewer, Alexander D. Douglas, Katharine A. Collins, Fenella D. Halstead, Sean C. Elias, Patrick J. Lillie, Kelly Rausch, Joan Aebig, Kazutoyo Miura, Nick J. Edwards, Ian D. Poulton, Angela Hunt-Cooke, David W. Porter, Fiona M. Thompson, Ros Rowland, Simon J. Draper, Sarah C. Gilbert, Michael P. Fay, Carole A. Long, Daming Zhu, Yimin Wu, Laura B. Martin, Charles F. Anderson, Alison M. Lawrie, Adrian V. S. Hill and Ruth D. Ellis
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria.
  2. (2009). A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
  3. (2009). A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
  4. (2009). A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.
  5. (2009). Anti-apicalmembrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
  6. (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.
  7. (2008). Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.
  8. (2010). Blood stage vaccines for Plasmodium falciparum: Current status and the way forward.
  9. (2008). Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.
  10. (2005). Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.
  11. (2009). Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.
  12. (2010). Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies.
  13. (2008). Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.
  14. Draper SJ Blood-stage malaria vaccines - recent progress and future challenges.
  15. (2000). Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers.
  16. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
  17. (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
  18. (2008). Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
  19. (2004). Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.
  20. (2010). Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.
  21. (2009). High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.
  22. (2002). High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers.
  23. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.
  24. (2006). Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
  25. (2010). In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.
  26. (2002). In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
  27. (2009). Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.
  28. (2007). Malaria. Did they really say … eradication?
  29. (1997). Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines.
  30. (2009). Multiple functions of human T cells generated by experimental malaria challenge.
  31. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
  32. (2008). Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.
  33. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
  34. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 AMA1
  35. (2002). Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection.
  36. (2005). Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
  37. (2009). Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines,
  38. (2007). Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update.
  39. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS
  40. (2011). Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis.
  41. (2004). Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction.
  42. (2009). The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria.
  43. (2010). The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.
  44. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparumspecific memory B cells in malaria-naive individuals.
  45. (2005). Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.